0000000000671836

AUTHOR

Michel Moutschen

showing 2 related works from this author

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabin…

2019

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed vira…

MaleDOLUTEGRAVIRSustained Virologic ResponseHIV InfectionsGastroenterologychemistry.chemical_compound0302 clinical medicineMedicine and Health SciencesEmtricitabine030212 general & internal medicinePharmacology & PharmacyDarunavir0303 health sciencesAlanineDrug SubstitutionCobicistatEmtricitabine Tenofovir Disoproxil Fumarate Drug CombinationLamivudineAntiretroviralsMiddle AgedViral LoadOPEN-LABEL3. Good healthWEIGHT-GAINDrug CombinationsTreatment OutcomeDolutegravirNON-INFERIORITYFemaleSafetyViral loadLife Sciences & Biomedicinemedicine.drugTabletsAdultmedicine.medical_specialtyEfficacyAnti-HIV AgentsRITONAVIREmtricitabineTENOFOVIR ALAFENAMIDELAMIVUDINETenofovir alafenamideSingle-tablet regimen03 medical and health sciencesInternal medicineVirologymedicineVIH (Virus)HumansSwitch studyProtease InhibitorsTenofovirDarunavirAgedPharmacologyScience & Technology030306 microbiologybusiness.industryHIV (Viruses)AdenineDarunavir/cobicistat/emtricitabine/TAFAntiretroviral agentsCOBICISTATMAINTENANCEchemistry[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHIV-1RitonavirCobicistat[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessRESISTANCE
researchProduct

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

2018

BACKGROUND: Familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) are monogenic autoinflammatory diseases characterized by recurrent fever flares. METHODS: We randomly assigned patients with genetically confirmed colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, or TRAPS at the time of a flare to receive 150 mg of canakinumab subcutaneously or placebo every 4 weeks. Patients who did not have a resolution of their flare received an add-on injection of 150 mg of canakinumab. The primary outcome was complete response (resolution…

Male0301 basic medicineInterleukin-1betaFamilial Mediterranean fever0302 clinical medicineMonoclonalChildMedicine(all)Mevalonate kinase deficiencySubcutaneousMedicine (all)Interleukin-1betaAntibodies MonoclonalGeneral MedicineFamilial Mediterranean FeverRecurrent feverChild PreschoolFemaleTumor necrosis factor alphaDrugInflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]medicine.drugAdultAdolescentFeverInjections SubcutaneousHereditary Autoinflammatory DiseasesAntibodies Monoclonal HumanizedAdolescent; Adult; Antibodies Monoclonal/administration & dosage; Antibodies Monoclonal/adverse effects; Antibodies Monoclonal/therapeutic use; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever/drug therapy; Female; Fever/drug therapy; Hereditary Autoinflammatory Diseases/drug therapy; Humans; Injections Subcutaneous; Interleukin-1beta/antagonists & inhibitors; Male; Mevalonate Kinase Deficiency/drug therapy; Young AdultAntibodiesInjectionsDose-Response RelationshipYoung Adult03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterDouble-Blind MethodGeneral & Internal MedicinemedicineHumansPreschoolAdolescent; Adult; Antibodies Monoclonal; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever; Female; Fever; Hereditary Autoinflammatory Diseases; Humans; Injections Subcutaneous; Interleukin-1beta; Male; Mevalonate Kinase Deficiency; Young Adult; Medicine (all)030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryHereditary Autoinflammatory DiseasesHyperimmunoglobulinemia Dmedicine.diseaseCanakinumab030104 developmental biologyImmunologyMevalonate Kinase Deficiencybusiness
researchProduct